Ocular Therapeutix, Inc. (OCUL) News
Filter OCUL News Items
OCUL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OCUL News Highlights
- OCUL's 30 day story count now stands at 4.
- Over the past 12 days, the trend for OCUL's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about OCUL are EYE, AGE and AMD.
Latest OCUL News From Around the Web
Below are the latest news stories about Ocular Therapeutix Inc that investors may wish to consider to help them evaluate OCUL as an investment opportunity.
Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue EstimatesTheravance Bio (TBPH) delivered earnings and revenue surprises of -43.33% and 4.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Ocular Therapeutix To Report Fourth Quarter and Year-End 2021 Financial ResultsBEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fourth quarter and year-end financial results on Monday, February 28, 2022, after the market close. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference |
Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial ResultsBEDFORD, Mass., February 22, 2022--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fourth quarter and year-end financial results on Monday, February 28, 2022, after the market close. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference |
Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360BEDFORD, Mass., February 11, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced its intention to present data at two medical meetings. Data from the Phase 1 Australian-based clinical trial of OTX-TKI, an axitinib intravitreal implant for the treatment of patients with wet age-related macular degeneration (wet AMD) and other retinal |
Ocular Therapeutix owner buys 50,000 shares worth ~$300K (NASDAQ:OCUL)Ocular Therapeutix < |
AffaMed Therapeutics begins dosing in China trial of DEXTENZA to treat ocular inflammationOcular Therapeutix < |
AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery PatientsBEDFORD, Mass., January 18, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that AffaMed Therapeutics dosed its first patient in a real-world setting study being conducted in China evaluating the safety and efficacy of DEXTENZA® (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain post-catara |
Hikari Power Ltd Buys Alphabet Inc, Vanguard Health Care ETF, Bristol-Myers Squibb Co, Sells ...Tokyo, M0, based Investment company Hikari Power Ltd (Current Portfolio) buys Alphabet Inc, Vanguard Health Care ETF, Bristol-Myers Squibb Co, Jack Henry & Associates Inc, Parker Hannifin Corp, sells Anheuser-Busch InBev SA/NV, The Kraft Heinz Co, Amarin Corp PLC, ADMA Biologics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Hikari Power Ltd. |
Ocular Therapeutix: Shaken By Covid, Perfectly Positioned For Long-Term GainsNo summary available. |
Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual ConferenceBEDFORD, Mass., January 04, 2022--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022. |